- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004354
Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees.
II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors).
III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA.
IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.
Study Overview
Status
Conditions
Detailed Description
PROTOCOL OUTLINE:
Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.
Study Type
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Diagnosed glucocorticoid-remediable aldosteronism (GRA) with hypertension Hypokalemia is variably seen Blood pressure variably elevated Elevated level of aldosterone Low level of plasma renin activity
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Robert G. Dluhy, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/11917
- BWH-91328603
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperaldosteronism
-
Haukeland University HospitalCompleted
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPrimary Hyperaldosteronism | Electrolyte DisturbanceGermany
-
University Hospital, CaenRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy | Essential Hypertension | Primary Hyperaldosteronism | Secondary HyperaldosteronismFrance
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
NovartisCompletedPrimary HyperaldosteronismFrance
-
University College, LondonUniversity College London Hospitals; Cambridge University Hospitals NHS Foundation... and other collaboratorsCompletedPrimary Hyperaldosteronism | Primary Hyperaldosteronism Due to Adrenal AdenomaUnited Kingdom
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingPrimary Aldosteronism | Aldosterone-Producing Adenoma | Idiopathic HyperaldosteronismChina
-
Imperial College LondonDr Katrina Ohla, Institute of Neuroscience and Medicine, Julich, GermanyUnknownHypertension | Hyperaldosteronism; Primary | Salt; Excess | Appetite DisordersUnited Kingdom
-
Radboud University Medical CenterCompletedPrimary HyperaldosteronismNetherlands